Syndax Pharmaceuticals Capital Expenditures Over Time

SNDX Stock  USD 14.29  0.19  1.31%   
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Syndax Pharmaceuticals Performance and Syndax Pharmaceuticals Correlation.
For more information on how to buy Syndax Stock please use our How to Invest in Syndax Pharmaceuticals guide.
  
Capital Expenditures is expected to grow at the current pace this year.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Syndax Pharmaceuticals. If investors know Syndax will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Syndax Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(3.72)
Revenue Per Share
0.277
Quarterly Revenue Growth
332.974
Return On Assets
(0.32)
Return On Equity
(0.76)
The market value of Syndax Pharmaceuticals is measured differently than its book value, which is the value of Syndax that is recorded on the company's balance sheet. Investors also form their own opinion of Syndax Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Syndax Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Syndax Pharmaceuticals' market value can be influenced by many factors that don't directly affect Syndax Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Syndax Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Syndax Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Syndax Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Specify up to 10 symbols:

Cross Equities Capital Expenditures Analysis

Compare Syndax Pharmaceuticals and related stocks such as Cogent Biosciences, Cullinan Oncology LLC, and Kalvista Pharmaceuticals Capital Expenditures Over Time
Select Fundamental
Price To Sales RatioDividend Yield
Ptb RatioDays Sales Outstanding
Book Value Per ShareFree Cash Flow Yield
Invested CapitalOperating Cash Flow Per Share
Average PayablesStock Based Compensation To Revenue
Capex To DepreciationPb Ratio
Ev To SalesFree Cash Flow Per Share
RoicInventory Turnover
Net Income Per ShareDays Of Inventory On Hand
Payables TurnoverSales General And Administrative To Revenue
Average InventoryResearch And Ddevelopement To Revenue
Capex To RevenueCash Per Share
PocfratioInterest Coverage
Payout RatioCapex To Operating Cash Flow
Pfcf RatioDays Payables Outstanding
Net Current Asset ValueIncome Quality
RoeTangible Asset Value
Ev To Operating Cash FlowPe Ratio
Return On Tangible AssetsEv To Free Cash Flow
Earnings YieldIntangibles To Total Assets
Net Debt To E B I T D ACurrent Ratio
Tangible Book Value Per ShareReceivables Turnover
Shareholders Equity Per ShareDebt To Equity
Capex Per ShareGraham Net Net
Average ReceivablesRevenue Per Share
Interest Debt Per ShareDebt To Assets
Enterprise Value Over E B I T D AGraham Number
Short Term Coverage RatiosPrice Earnings Ratio
Operating CyclePrice Book Value Ratio
Price Earnings To Growth RatioDays Of Payables Outstanding
Dividend Payout RatioPrice To Operating Cash Flows Ratio
Price To Free Cash Flows RatioPretax Profit Margin
Ebt Per EbitOperating Profit Margin
Effective Tax RateCompany Equity Multiplier
Long Term Debt To CapitalizationTotal Debt To Capitalization
Return On Capital EmployedDebt Equity Ratio
Ebit Per RevenueQuick Ratio
Dividend Paid And Capex Coverage RatioNet Income Per E B T
Cash RatioCash Conversion Cycle
Operating Cash Flow Sales RatioDays Of Inventory Outstanding
Days Of Sales OutstandingFree Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage RatiosPrice To Book Ratio
Fixed Asset TurnoverCapital Expenditure Coverage Ratio
Price Cash Flow RatioEnterprise Value Multiple
Debt RatioCash Flow To Debt Ratio
Price Sales RatioReturn On Assets
Asset TurnoverNet Profit Margin
Gross Profit MarginPrice Fair Value
Return On Equity
2010201120122013201420152016201720182019202020212022202320242025
COGTMMMMMM3.3 M912 K549 K33 K320 K1.7 M6.9 M2.8 M573 K544.4 K
CGEM0.00.00.00.00.00.00.0261 K261 K20 K10 K589.2 K1.1 M208 K0.00.0
KALV91 K91 K91 K18 K159 K659 K74 K1.4 M1.1 M220 K82 K931 K1.2 M443 K659 K491.4 K
MRSN619 K619 K619 K619 K619 K619 K1.1 M1.1 M1.4 M605 K473 K648 K2.2 M2.2 M132 K125.4 K
PLRX1.4 M1.4 M1.4 M1.4 M1.4 M1.4 M1.4 M1.4 M2.3 M964 K1.5 MM1.8 M921 K3.8 MM
RVMD1.6 M1.6 M1.6 M1.6 M1.6 M1.6 M1.6 M1.6 M1.5 M2.6 M2.9 M6.5 M10.8 M7.7 M10.3 MM
VRDN106.9 K106.9 K106.9 K4.8 K266 K123 KK246 K445 K84 K42 K338 K797 K898 K511 K327 K
INZY259 K259 K259 K259 K259 K259 K259 K259 K259 K139 K568 K397 K410 K298 K342.7 K379.7 K
AVTE181 K181 K181 K181 K181 K181 K181 K181 K181 K181 K181 K181 K195 K142 K127.8 K140.8 K
KROS217 K217 K217 K217 K217 K217 K217 K217 K217 K271 K294 KM1.2 M2.5 M1.9 M1.2 M
MLYS0.00.00.00.00.00.00.00.00.00.00.00.00.00.096 K100.8 K
REPL238 K238 K238 K238 K238 K238 K238 K136 K2.6 M6.5 M2.4 M2.3 M2.3 M5.7 M6.5 M6.8 M
PCVX1.2 K1.2 K1.2 K1.2 K1.2 K1.2 K1.2 K1.2 K1.8 M1.2 M1.2 M6.6 M5.8 M67.9 M22.4 M14.7 M
LRMR58 K58 K58 K58 K58 K595 K660 K55 K108 K83 K62 K333 K100 K164 K147.6 K177.4 K
MRUS114.6 K114.6 K114.6 K114.6 K190.9 K112.6 K521.6 K868.6 K4.2 M2.6 M1.3 M870 K7.6 MM1.7 M2.2 M
STRO4.4 M4.4 M4.4 M4.4 M4.4 M4.4 M4.4 M3.3 M1.6 M3.5 M7.1 M15.3 M7.9 M4.3 MM6.5 M
CYTK6.6 M443 K125 K542 K1.1 M562 K1.6 M2.9 M889 K2.6 M11.1 M48.9 M11.3 M1.4 M3.9 M5.2 M
EWTX180 K180 K180 K180 K180 K180 K180 K180 K180 K180 K203 K668 K5.5 M5.7 M1.3 M2.5 M
DYN0.0242 M0.098 M0.0275 M326 M224 M134 K1.6 M1.2 M3.6 M3.1 M729 K2.4 M2.3 M

Syndax Pharmaceuticals and related stocks such as Cogent Biosciences, Cullinan Oncology LLC, and Kalvista Pharmaceuticals Capital Expenditures description

Capital Expenditures are funds used by Syndax Pharmaceuticals to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Syndax Pharmaceuticals operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.

My Equities

My Current Equities and Potential Positions

Syndax Pharmaceuticals
SNDX
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
LocationMassachusetts; U.S.A
ExchangeNASDAQ Exchange
USD 14.29

Additional Tools for Syndax Stock Analysis

When running Syndax Pharmaceuticals' price analysis, check to measure Syndax Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Syndax Pharmaceuticals is operating at the current time. Most of Syndax Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Syndax Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Syndax Pharmaceuticals' price. Additionally, you may evaluate how the addition of Syndax Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.